MedMira Inc. (MMIRF)
USD 0.02
(-70.43%)
USD 0.02
(-70.43%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 18.68 Million CAD | 15.43% |
| 2022 | 16.18 Million CAD | -17.48% |
| 2021 | 19.61 Million CAD | 3.46% |
| 2020 | 18.95 Million CAD | 37.68% |
| 2019 | 13.76 Million CAD | 17.7% |
| 2018 | 11.69 Million CAD | 21.13% |
| 2017 | 9.65 Million CAD | 13.2% |
| 2016 | 8.53 Million CAD | -10.08% |
| 2015 | 9.48 Million CAD | 11.21% |
| 2014 | 8.53 Million CAD | -16.98% |
| 2013 | 10.27 Million CAD | -12.0% |
| 2012 | 11.67 Million CAD | -43.32% |
| 2011 | 20.6 Million CAD | 19.58% |
| 2010 | 17.23 Million CAD | 4.31% |
| 2009 | 16.52 Million CAD | 11.82% |
| 2008 | 14.77 Million CAD | -5.55% |
| 2007 | 15.64 Million CAD | 29.77% |
| 2006 | 12.05 Million CAD | 7.31% |
| 2005 | 11.23 Million CAD | 48.44% |
| 2004 | 7.56 Million CAD | 66.42% |
| 2003 | 4.54 Million CAD | -57.93% |
| 2002 | 10.8 Million CAD | 19.65% |
| 2001 | 9.03 Million CAD | 31.06% |
| 2000 | 6.89 Million CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 23.22 Million CAD | 13.04% |
| 2024 Q1 | 20.39 Million CAD | 9.18% |
| 2024 Q2 | 20.54 Million CAD | 0.73% |
| 2023 Q2 | 17.2 Million CAD | 2.61% |
| 2023 Q1 | 16.76 Million CAD | 3.58% |
| 2023 FY | 18.68 Million CAD | 15.43% |
| 2023 Q3 | 17.89 Million CAD | 4.04% |
| 2023 Q4 | 18.68 Million CAD | 4.39% |
| 2022 Q3 | 15.99 Million CAD | -0.28% |
| 2022 Q1 | 21.08 Million CAD | 7.49% |
| 2022 FY | 16.18 Million CAD | -17.48% |
| 2022 Q2 | 16.03 Million CAD | -23.95% |
| 2022 Q4 | 16.18 Million CAD | 1.22% |
| 2021 Q4 | 19.61 Million CAD | 1.81% |
| 2021 Q1 | 19.4 Million CAD | 2.37% |
| 2021 Q2 | 19.24 Million CAD | -0.83% |
| 2021 FY | 19.61 Million CAD | 3.46% |
| 2021 Q3 | 19.26 Million CAD | 0.09% |
| 2020 Q4 | 18.95 Million CAD | 3.09% |
| 2020 Q1 | 16.65 Million CAD | 20.92% |
| 2020 Q2 | 17.43 Million CAD | 4.7% |
| 2020 Q3 | 18.39 Million CAD | 5.5% |
| 2020 FY | 18.95 Million CAD | 37.68% |
| 2019 Q4 | 13.76 Million CAD | 3.29% |
| 2019 Q1 | 12.2 Million CAD | 4.31% |
| 2019 FY | 13.76 Million CAD | 17.7% |
| 2019 Q2 | 12.86 Million CAD | 5.44% |
| 2019 Q3 | 13.33 Million CAD | 3.61% |
| 2018 Q3 | 11.17 Million CAD | 5.39% |
| 2018 Q4 | 11.69 Million CAD | 4.71% |
| 2018 FY | 11.69 Million CAD | 21.13% |
| 2018 Q1 | 10.15 Million CAD | 5.18% |
| 2018 Q2 | 10.6 Million CAD | 4.36% |
| 2017 Q1 | 8.53 Million CAD | 0.07% |
| 2017 Q4 | 9.65 Million CAD | 5.7% |
| 2017 Q3 | 9.13 Million CAD | 7.46% |
| 2017 Q2 | 8.5 Million CAD | -0.4% |
| 2017 FY | 9.65 Million CAD | 13.2% |
| 2016 FY | 8.53 Million CAD | -10.08% |
| 2016 Q4 | 8.53 Million CAD | 7.36% |
| 2016 Q1 | 8.35 Million CAD | -11.98% |
| 2016 Q3 | 7.94 Million CAD | -6.23% |
| 2016 Q2 | 8.47 Million CAD | 1.49% |
| 2015 Q4 | 9.48 Million CAD | 9.21% |
| 2015 FY | 9.48 Million CAD | 11.21% |
| 2015 Q2 | 8.91 Million CAD | 7.06% |
| 2015 Q1 | 8.32 Million CAD | -2.41% |
| 2015 Q3 | 8.68 Million CAD | -2.53% |
| 2014 FY | 8.53 Million CAD | -16.98% |
| 2014 Q4 | 8.53 Million CAD | 2.82% |
| 2014 Q3 | 8.29 Million CAD | -6.66% |
| 2014 Q2 | 8.88 Million CAD | -7.47% |
| 2014 Q1 | 9.6 Million CAD | -6.52% |
| 2013 Q1 | 10.76 Million CAD | -7.82% |
| 2013 FY | 10.27 Million CAD | -12.0% |
| 2013 Q4 | 10.27 Million CAD | 11.59% |
| 2013 Q3 | 9.21 Million CAD | 5.07% |
| 2013 Q2 | 8.76 Million CAD | -18.58% |
| 2012 Q3 | 23.5 Million CAD | 7.35% |
| 2012 Q2 | 21.89 Million CAD | 1.94% |
| 2012 Q1 | 21.47 Million CAD | 4.22% |
| 2012 FY | 11.67 Million CAD | -43.32% |
| 2012 Q4 | 11.67 Million CAD | -50.31% |
| 2011 Q3 | 19.49 Million CAD | 4.44% |
| 2011 Q1 | 18.39 Million CAD | 6.77% |
| 2011 FY | 20.6 Million CAD | 19.58% |
| 2011 Q4 | 20.6 Million CAD | 5.72% |
| 2011 Q2 | 18.66 Million CAD | 1.43% |
| 2010 Q1 | 15.84 Million CAD | -4.07% |
| 2010 Q2 | 15.52 Million CAD | -2.04% |
| 2010 Q3 | 15.97 Million CAD | 2.89% |
| 2010 Q4 | 17.23 Million CAD | 7.88% |
| 2010 FY | 17.23 Million CAD | 4.31% |
| 2009 Q3 | 16.49 Million CAD | 2.02% |
| 2009 FY | 16.52 Million CAD | 11.82% |
| 2009 Q1 | 15.89 Million CAD | 7.62% |
| 2009 Q2 | 16.17 Million CAD | 1.72% |
| 2009 Q4 | 16.52 Million CAD | 0.13% |
| 2008 Q4 | 14.77 Million CAD | 3.84% |
| 2008 FY | 14.77 Million CAD | -5.55% |
| 2008 Q3 | 14.22 Million CAD | -7.81% |
| 2008 Q2 | 15.43 Million CAD | -3.31% |
| 2008 Q1 | 15.96 Million CAD | 2.04% |
| 2007 Q3 | 14.71 Million CAD | 1.97% |
| 2007 FY | 15.64 Million CAD | 29.77% |
| 2007 Q2 | 14.43 Million CAD | 9.91% |
| 2007 Q4 | 15.64 Million CAD | 6.29% |
| 2007 Q1 | 13.13 Million CAD | 8.94% |
| 2006 Q3 | 10.34 Million CAD | -28.79% |
| 2006 Q4 | 12.05 Million CAD | 16.51% |
| 2006 FY | 12.05 Million CAD | 7.31% |
| 2006 Q1 | 13.22 Million CAD | 17.77% |
| 2006 Q2 | 14.52 Million CAD | 9.82% |
| 2005 Q1 | 7.99 Million CAD | 5.71% |
| 2005 FY | 11.23 Million CAD | 48.44% |
| 2005 Q3 | 9.47 Million CAD | 2.98% |
| 2005 Q4 | 11.23 Million CAD | 18.55% |
| 2005 Q2 | 9.2 Million CAD | 15.02% |
| 2004 FY | 7.56 Million CAD | 66.42% |
| 2004 Q1 | 4.71 Million CAD | 3.61% |
| 2004 Q4 | 7.56 Million CAD | 15.83% |
| 2004 Q2 | 5.66 Million CAD | 20.17% |
| 2004 Q3 | 6.53 Million CAD | 15.39% |
| 2003 Q4 | 4.54 Million CAD | -60.41% |
| 2003 FY | 4.54 Million CAD | -57.93% |
| 2003 Q1 | 10.69 Million CAD | -1.08% |
| 2003 Q2 | 10.41 Million CAD | -2.63% |
| 2003 Q3 | 11.48 Million CAD | 10.31% |
| 2002 Q3 | 11.38 Million CAD | 4.79% |
| 2002 FY | 10.8 Million CAD | 19.65% |
| 2002 Q4 | 10.8 Million CAD | -5.07% |
| 2002 Q1 | 9.99 Million CAD | 0.0% |
| 2002 Q2 | 10.86 Million CAD | 8.75% |
| 2001 FY | 9.03 Million CAD | 31.06% |
| 2000 FY | 6.89 Million CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 50.26 Million USD | 62.829% |
| Skye Bioscience, Inc. | 14.07 Million USD | -32.768% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 68.341% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -2210.039% |
| Qrons Inc. | 1.48 Million USD | -1155.007% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.9 Million USD | -17.472% |
| CSL Limited | 18.62 Billion USD | 99.9% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 74.219% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -97.376% |
| Regen BioPharma, Inc. | 5.45 Million USD | -242.337% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 75.062% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -41701.184% |
| Rebus Holdings, Inc. | 5.24 Million USD | -256.418% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -68005.774% |
| Neon Bloom, Inc. | 1.22 Million USD | -1423.671% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -9189.891% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 64.95% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -94.984% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -4331.896% |
| SQZ Biotechnologies Company | 50.03 Million USD | 62.662% |
| Intellipharmaceutics International Inc. | 12 Million USD | -55.582% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -385.105% |
| Mesoblast Limited | 188.44 Million USD | 90.085% |
| Marizyme, Inc. | 26.67 Million USD | 29.961% |
| Genus plc | 485 Million USD | 96.148% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -219.779% |
| Pharming Group N.V. | 244.07 Million USD | 92.345% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -829.465% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -642.489% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -391.67% |
| ContraFect Corporation | 32.53 Million USD | 42.567% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -842.986% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -388.118% |
| IMV Inc. | 37.93 Million USD | 50.746% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -58.628% |
| MultiCell Technologies, Inc. | 1617.67 USD | -1154860.962% |
| ONE Bio Corp. | 27.49 Million USD | 32.05% |
| Accustem Sciences Inc. | 1.07 Million USD | -1631.17% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 75.866% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -783.35% |
| Q BioMed Inc. | 8.13 Million USD | -129.726% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 77.472% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -263.065% |
| Biomind Labs Inc. | 1.49 Million USD | -1146.717% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 84.263% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -106.625% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -1.522% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -1203.017% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -13048.568% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -225.166% |
| GB Sciences, Inc. | 5.41 Million USD | -244.869% |
| Alpha Cognition Inc. | 7.16 Million USD | -160.768% |
| HST Global, Inc. | 593.59 Thousand USD | -3047.52% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -1383.764% |
| Halberd Corporation | 728.71 Thousand USD | -2463.877% |
| Enzolytics Inc. | 365.26 Million USD | 94.885% |
| Agentix Corp. | 2.51 Million USD | -644.196% |
| Resverlogix Corp. | 67.39 Million USD | 72.278% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -2127.584% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 95.801% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -990.05% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 24.499% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -56.963% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -409.758% |
| AVAX Technologies, Inc. | 3.99 Million USD | -367.818% |
| Zenith Capital Corp. | 27.56 Thousand USD | -67669.803% |
| Genscript Biotech Corporation | 1.32 Billion USD | 98.591% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -7728.68% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -400.319% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -2644.202% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -589.009% |
| Kadimastem Ltd | 3.5 Million USD | -433.072% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -27815.339% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -3920.55% |
| LadRx Corporation | 2.2 Million USD | -749.044% |
| Cell Source, Inc. | 15.8 Million USD | -18.2% |
| Regen BioPharma, Inc. | 5.45 Million USD | -242.337% |
| NovAccess Global Inc. | 7.86 Million USD | -137.681% |
| Affymax, Inc. | 8.87 Million USD | -110.613% |
| Itoco Inc. | 1.65 Million USD | -1030.172% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -810.693% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -208.869% |
| Mobile Lads Corp. | 1.31 Million USD | -1322.421% |
| CytoDyn Inc. | 127.89 Million USD | 85.391% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -44598.335% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -1092.782% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -69.153% |
| SYBLEU INC | 681.41 Thousand USD | -2641.87% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -206.191% |
| International Stem Cell Corporation | 5.27 Million USD | -254.055% |
| Bioxytran, Inc. | 3.24 Million USD | -474.964% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -2885.489% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -304.656% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 54.426% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 16.086% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -822.464% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -241.063% |
| Neutra Corp. | 973.52 Thousand USD | -1819.147% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 35.608% |
| PureTech Health plc | 125.58 Million USD | 85.123% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -397.281% |
| IXICO plc | 1.9 Million USD | -883.189% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 8.99% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 81.918% |
| CSL Limited | 18.62 Billion USD | 99.9% |
| Cellectis S.A. | 249.36 Million USD | 92.508% |